ResearchPublications

National Institute on Drug Abuse Clinical Trials Network meeting report: Advancing emergency department initiation of buprenorphine for opioid use disorder
Abstract

Opioid use disorder and opioid overdose deaths are a major public health crisis, yet highly effective evidence-based treatments are available that reduce morbidity and mortality. One such treatment, buprenorphine, can be initiated in the emergency department (ED). Despite evidence of efficacy and effectiveness for ED-initiated buprenorphine, universal uptake remains elusive. On November 15 and 16, 2021, the National Institute on Drug Abuse Clinical Trials Network convened a meeting of partners, experts, and federal officers to identify research priorities and knowledge gaps for ED-initiated buprenorphine. Meeting participants identified research and knowledge gaps in 8 categories, including ED staff and peer-based interventions; out-of-hospital buprenorphine initiation; buprenorphine dosing and formulations; linkage to care; strategies for scaling ED-initiated buprenorphine; the effect of ancillary technology-based interventions; quality measures; and economic considerations. Additional research and implementation strategies are needed to enhance adoption into standard emergency care and improve patient outcomes.

Download PDF

Full citation:
Cowan E, Perrone J, Bernstein SL, Coupet E, Fiellin DA, Hawk K, Herring A, Huntley K, McCormack R, Venkatesh A, D'Onofrio G (2023).
National Institute on Drug Abuse Clinical Trials Network meeting report: Advancing emergency department initiation of buprenorphine for opioid use disorder
Annals of Emergency Medicine, 82 (3), 326-335. doi: 10.1016/j.annemergmed.2023.03.025. PMCID: PMC10524880.